psilocin

psilocybine minus the phosphate ester; RN given refers to parent cpd; structure

Also Known As:

(3-(2-dimethylamino)ethyl)indol-4-ol; psilocin hydrochloride; psilocin tartrate (1:1)

Networked: 17 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Psilocybin: 423
      - psilocin: 17
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Tryptamines: 1679
        Psilocybin: 423
        psilocin: 17
      - Indole Alkaloids: 200
        Psilocybin: 423
        psilocin: 17
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Psilocybin: 423
        psilocin: 17

Experts

1.	Bannerman, David M: 1 article (01/2022)
2.	Blanco-Duque, Cristina: 1 article (01/2022)
3.	Bréant, Benjamin J: 1 article (01/2022)
4.	Goodwin, Guy M: 1 article (01/2022)
5.	Hackl, Benjamin: 1 article (01/2022)
6.	Hilber, Karlheinz: 1 article (01/2022)
7.	Khandelia, Himanshu: 1 article (01/2022)
8.	Koenig, Xaver: 1 article (01/2022)
9.	Kubista, Helmut: 1 article (01/2022)
10.	Lund, Frederik Wendelboe: 1 article (01/2022)

Related Diseases

1.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 12/01/2019 - "Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. "
2.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2022 - "Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electrocardiogram attributed to the drug's main metabolite, psilocin, gave rise to safety concerns. " 01/01/2022 - "Here we show that clinical concentrations of psilocin do not cause significant human ether-a-go-go-related gene (hERG) potassium channel inhibition, a major risk factor for adverse cardiac events. "
3.	Hallucinations (Hallucination) 10/24/2023 - "Furthermore, psilocin, DOI, and TCB-2 treatment did not affect the spontaneous locomotor activity or head-twitch response, a hallucination-like behavior in rodents. " 07/07/2023 - "Furthermore, psilocin, DOI, and TCB-2 treatment did not affect the spontaneous locomotor activity or head-twitch response, a hallucination-like behavior in rodents. " 12/01/2022 - "Activation of this system by psilocybin and psilocin may produce temporary changes in the brain that induce hallucinations and feelings of euphoria. " 07/01/2007 - "There are estimated to be as many as eight Psilocybe hallucinogenic species containing psychoactive alkaloids, such as psilocybin and psilocin, which may cause visual, auditory and other hallucinations, as well as profound changes in the perception of time and space. "
4.	Mental Disorders (Mental Disorder) 07/01/2023 - "Psilocin, the bio-active form of psilocybin, can potentially treat various psychiatric diseases. " 01/01/2023 - "Psilocybin and its active metabolite psilocin have been shown to elicit rapid and long-lasting symptom improvements in a variety of affective psychiatric illnesses. " 01/01/2023 - "Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. "
5.	Treatment-Resistant Depressive Disorder 01/01/2022 - "The active hallucinogen of magic mushrooms, psilocin, is being repurposed to treat nicotine addiction and treatment-resistant depression. "

Related Drugs and Biologics

1.	Psilocybin (Psilocibin)
2.	Prodrugs
3.	Lysergic Acid Diethylamide (LSD)
4.	Mescaline (Peyote)
5.	Hallucinogens (Psychedelics)
6.	Potassium Channels (Potassium Channel)
7.	Ether (Diethyl Ether)
8.	N,N-Dimethyltryptamine (Dimethyltryptamine)
9.	Alkaloids
10.	tryptamine

Related Therapies and Procedures

1.	Therapeutics
2.	Electrodes (Electrode)